The Medicines and Healthcare products Regulatory Agency has validated the Marketing Authorisation Application of exa-cel for the treatment of sickle cell disease and transfusion-dependent beta thalassemia in Great Britain.

The platform will be used to sequence genomic information from a patient’s tumor sample to identify the unique genetic mutations that are most likely to generate a tailored antitumor response.

German Pharma company Cheplapharm has selected the CARA Life Science Platform to standardize and unify their Regulatory, RIM, Quality and Labelling processes across departmental boundaries.

GenNext Technologies, Inc. has announced that Dr. John L. Grant has joined its Board of Directors.

TTP plc has today announced the launch of Cellular Origins, a TTP spin-out, created to enable scalable, cost-effective and efficient manufacture of cell and gene therapies.

FUJIFILM Irvine Scientific, Inc. has announced the launch of its BalanCD HEK293 Viral Feed.

Pheno Therapeutics Limited has announced that it has entered into an exclusive worldwide license agreement with UCB.

AMSBIO reports how the Faculty of Biological Sciences at the University of Leeds (UK) is using their specialty reagents for the production, visualization and analysis of glycans and to investigate their interactions which are instrumental to the advance of glycobiology.

Fraunhofer IZI intends to digitalize its manufacturing operations with MODA-ES®, the Manufacturing Execution System from Lonza.

Under the terms of the agreement, Curamys obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.